Skip to content
Open access · US-GOV via ClinicalTrials.gov Clinical trial

Investigation of the Maximal Treatment Interval and Long-term Remission and the Associated Factors of Neovascular AMD Treated With Anti-VEGF Using Treat and Extend Strategy

Authors not listed

Shin Kong Wu Ho-Su Memorial Hospital · 2022

Abstract

To evaluate the duration of effectiveness of anti-VEGF (Aflibercept) by analyzing the percentage of patients whose maximum treatment interval is extended to 16 weeks and beyond in 24 months and their long-term remission.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
ClinicalTrials.gov
Canonical
link ↗
Fetched
2026-11-12 MST

Cite this

APA
Anonymous. (2022). Investigation of the Maximal Treatment Interval and Long-term Remission and the Associated Factors of Neovascular AMD Treated With Anti-VEGF Using Treat and Extend Strategy. <em>Shin Kong Wu Ho-Su Memorial Hospital</em>. https://clinicaltrials.gov/study/NCT05342857
Vancouver
Anonymous. Investigation of the Maximal Treatment Interval and Long-term Remission and the Associated Factors of Neovascular AMD Treated With Anti-VEGF Using Treat and Extend Strategy. Shin Kong Wu Ho-Su Memorial Hospital. 2022.
BibTeX
@misc{anon2022Invest, title = {Investigation of the Maximal Treatment Interval and Long-term Remission and the Associated Factors of Neovascular AMD Treated With Anti-VEGF Using Treat and Extend Strategy}, author = {Anonymous}, journal = {Shin Kong Wu Ho-Su Memorial Hospital}, year = {2022}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings